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Dr Steven DeMeester (Los Angeles, Calif). The authors
reviewed their database from July 2005 to 2011 for clinically
staged patients, carcinoma in situ or T1, and had biopsies showing
high-grade dysplasia or invasive cancer. All the patients had EUS,
and thosewith EUS, clinical stage T2 or greater, biopsy-proven N1
disease, and neoadjuvant therapy were excluded. The final resec-
tion pathology was then used to assess the accuracy of EUS for
T and N staging.
My first question is why did the authors choose to go at it
seemingly backward? In other words, why not start with all
pathologically staged high-grade dysplasia or T1 cancers and go
back and analyze how these patients were clinically staged? Given
the shown and known inaccuracy of EUS for both Tand N staging,
howmany of the incorrectly staged T patients, such as those staged
T2 clinically and were therefore excluded from your analysis,
might have actually been T1a lesions that you should have
included, and, likewise, by excluding known N1 disease, how
many of those patients might have had a submucosal tumor and
were therefore excluded, thereby altering the true prevalence of
your nodal disease in this patient group?
Dr Bergeron. We chose to select first for the clinical staging
based on EUS because this is the typical decision-making process
that occurs for patients who are to undergo endoluminal therapies.
That is what led to our study design.
Dr DeMeester. It might be worth looking backward at it
again and just see if you come up with different numbers because
that is an important issue with the mis-staging that you have
demonstrated.
It has been well demonstrated that even with high-frequency 20
MHz ultrasound probes, differentiation between lamina propria
and muscularis mucosa invasion is difficult. I would suggest that
it is simply not possible with standard 7.5 and 12 MHz probes.
What was the impetus to try to distinguish between those with
12.5 or 7.5 MHz probes, the standard probes? Who was doing
the re-reviews? Was this you or your gastroenterology colleagues
or a combination of them?
Dr Bergeron. It was a combination as far as the review. The 20
MHz probes, some claim to be able to differentiate lamina propria
from muscularis mucosa invasion. However, surprisingly, in
the majority of the EUS reports, which included only the 7.5 or
12 MHz probes, the gastroenterologists performing the EUS
did differentiate that the tumor was invading the lamina propria
versus the muscularis mucosa. This information was routinely
included.
Dr DeMeester. I would suggest that as someonewho does them
himself, that’s simply not possible. Did you re-review the final
pathology as well? Oftentimes pathologists, particularly a number
of years ago before endoscopic resection became an important part
of the staging system, weren’t differentiating between T1a and
T1b because at that time it was all T1 lesions for them. Did you
go back and look at the pathology or had they already done a
good job of determining the precise depth of invasion on your final
pathology?
Dr Bergeron. In all of our pathologic analysis, T1a was
differentiated from T1b in the original final pathology reports.
Dr DeMeester. You demonstrated that there was only 1 patient
with an intramucosal tumor who had lymph node positivity. He772 The Journal of Thoracic and Cardiovascular Surghad invasion into the muscularis mucosa layer. But you had a small
number of patients, only 11, with invasion into the muscularis
mucosa. Larger series, such as ours, in which we had in excess
of 50 patients with invasion to the muscularis mucosa level
demonstrated only 1 patient. In other words, if you just look at
the mucosal layer alone, only 1.7% of your patients had a positive
lymph node, which compares favorably to other series. Are you
factoring that in, or are you choosing to select muscularis
mucosal invasion as a marker against endoscopic therapy, sort of
in contrast to what is accepted by most other centers for
endoscopic therapy?
Dr Bergeron. Yes, that is correct. In our experience, we had
only 1 tumor that invaded the muscularis mucosa that did have
positive nodes, and if you look at a lot of the endoscopic or
endoluminal-based therapy studies, there is a low percentage
rate of positive nodes with mucosal invasion. However, in a
previously reported study looking at minimally invasive
esophagectomy specimens, they had an approximate 6% rate of
positive lymph nodes with invasion into the muscularis mucosa.
The take-away from our review is that simply not just mucosal
invasion would be an indication for endoluminal therapy, but
potentially the more superficial lesion with only involvement of
the lamina propria might be more acceptable.
Dr DeMeester. Just one quick comment. I know your final
slide said that esophagectomy should still be considered the stan-
dard of care. I suggest that unless we as surgeons embrace
endoscopic therapy and take it on and incorporate it into our
practices, I fear for our specialty’s long-term involvement in
the esophagus.
Dr Robert Cerfolio (Birmingham, Ala). Our experience has
been similar, and I want to echo Steve’s point about us needing
to be involved. I have 2 quick questions. One, did you stratify
your data based on the endosonographer, that is, you versus the
gastroenterologist?
Dr Bergeron. All of the endosonography that was performed
was performed by gastroenterologists in this study.
Dr Cerfolio. I thought you said you were doing it when Steve
asked you.
Dr Bergeron. No. We reviewed the EUS studies, but thoracic
surgeons were not the physicians performing the endosonography.
Dr Cerfolio. So you mean you were just looking at the
ultrasound after they would do it?
Dr Bergeron.Yes. Or we were able to take the level of sublevel
of lesion penetration depth directly from the report as described by
the endosonographer.
DrCerfolio.That’s not theway to do it. I mean if you’re going to
do it, be the endosonographer and get involved. It would be inter-
esting to see if surgeons do it differently. Certainly with endobron-
chial ultrasound, I don’t think there are data yet, but I think it’s
coming that we’re going to be a little bit better at it, and I wonder
if that applies to EUS. I would like to see data on that.
You didn’t show me what you did with the patient who
has T1N1, unsuspected N1. Are you giving him adjuvant
chemotherapy when you present him at their tumor conference?
We have had incredibly heated debates. I know I don’t know
what to do. Maybe you can tell me what to tell this patient who I
have to call later today about unsuspected N1 disease; 41 nodes
were taken out, and he had 2 N1 nodes positive. He did not getery c February 2014
Bergeron et al General Thoracic Surgeryneoadjuvant therapy. Do you treat him, and if you treat him, what
do you treat him with? He’s a healthy guy, can tolerate anything,
doing great, and Eastern Cooperative Oncology Group status is
zero.
Dr Bergeron. I don’t know the answer to that. In general,
I would suspect that a patient with nodal disease would receive
adjuvant therapy at our institution if age were not prohibitive.The Journal of Thoracic and CaDr Cerfolio. You don’t know if they were treated?
Dr Bergeron. I don’t.
Dr Cerfolio. Anybody in the audience want to educate me as to
what they’re doing? (Inaudible voices from the audience.)
Dr Cerfolio. Mark Krasna said postoperative radiation and
chemotherapy. Dr DeMeester said less than 3 nodes, don’t do
anything. Interesting.rdiovascular Surgery c Volume 147, Number 2 773
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